A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

NCT02340611 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Olaparib
DRUG: Cediranib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]